12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adasuve staccato loxapine regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA for Adasuve Staccato loxapine to treat mild to moderate agitation in adults with schizophrenia or...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >